UPDATED
Strides hamstrung by US FDA Form 483
Strides announced that a US FDA inspection of its Bangalore facility has resulted in a Form 483, noting three observations.
Archives for September 20, 2018
Allergan and Sosei suspend development on Alzheimer’s drug
Sosei has voluntarily suspended development on its Alzheimer’s drug, co-licensed with Allergan, after toxicological effects were reported.
Aucta and Catalent enter commercial supply agreement
Aucta and Catalent entered a commercial supply agreement for vigabatrin to employ Catalent’s new drug packaging technology.
Phesi files patent for clinical trial protocol development method, system
The clinical development services provider Phesi is looking to patent its method and system for developing clinical trial protocols – which enables faster patient enrollment and study completion, says CEO.
GeneOne signs licensing agreement for RNA development
VGXI, a subsidiary of GeneOne, signed a licensing agreement with Houston Methodist Research Institute to produce RNA one of the most valued clinical ingredients.